Resource type
Thesis type
M.B.A
Date created
2007
Authors/Contributors
Author: Wildman, Julie Laura
Abstract
This is an analysis of a biotech company's license partnering opportunities. The company
(referred to as Company X) has a product candidate in Phase II clinical trials but does not have the resources or expertise needed to take this candidate through to commercial production and sales. As a result, Company X is seeking to enter into a license agreement with a large pharmaceutical company.
This analysis provides an overview of the biotech and target disease markets, as well as
an overview of the typical components of biotech license deals. The analysis then considers the
elements that are included in forecasts and valuation models when determining the value of a
biotech product candidate, and specifically examines the assumptions in Company X's valuation
model and its outputs. It also considers multiple criteria against which to evaluate potential
license partners.
(referred to as Company X) has a product candidate in Phase II clinical trials but does not have the resources or expertise needed to take this candidate through to commercial production and sales. As a result, Company X is seeking to enter into a license agreement with a large pharmaceutical company.
This analysis provides an overview of the biotech and target disease markets, as well as
an overview of the typical components of biotech license deals. The analysis then considers the
elements that are included in forecasts and valuation models when determining the value of a
biotech product candidate, and specifically examines the assumptions in Company X's valuation
model and its outputs. It also considers multiple criteria against which to evaluate potential
license partners.
Document
Copyright statement
Copyright is held by the author.
Scholarly level
Language
English
Member of collection
| Download file | Size |
|---|---|
| etd2966.pdf | 3.13 MB |